Sagimet Biosciences advances AURORA U.S. Phase 3 denifanstat trial
Sagimet Biosciences advances its AURORA U.S. Phase 3 trial of denifanstat in acne toward patient enrollment in Q4 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.